Kiora Pharmaceuticals granted new patent for KIO-104, says H.C. Wainwright

H.C. Wainwright reiterates a Buy rating and $10 price target on shares of Kiora Pharmaceuticals (KPRX) after the company announced that it received received a U.S. patent covering KIO-104 for the treatment of ocular diseases, including ocular inflammation, uveitis, age-related macular degeneration, and complications from refractive surgery. The patent covers varying dosing schedules, necessary excipients, and other novel methods for optimizing treatment of ocular inflammatory diseases, the analyst tells investors in a research note. The new patent should strengthen the company’s IP portfolio and help secure the potential market prospects if KIO-104 is successfully developed in clinical studies, the firm says.